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Iron(III) fumarate materials are well suited for biomedical applications as they feature biocompatible building blocks, porosity, chem-
ical functionalizability, and magnetic resonance imaging (MRI) activity. The synthesis of these materials however is difficult to 
control and it has been challenging to produce monodisperse particle sizes and morphologies that are required in medical use. Here, 
we report the optimization of iron(III) fumarate nano and microparticles synthesis by surfactant-free methods, including room tem-
perature, solvothermal, microwave, and microfluidic conditions. Four variants of iron(III) fumarate with distinct morphologies were 
isolated and are characterized in detail. Structural characterization shows that all iron(III) fumarate variants exhibit the metal-organic 
framework (MOF) structure of MIL-88A. Nanoparticles with a diameter of 50 nm were produced, which contain crystalline areas not 
exceeding 5 nm. Solvent-dependent swelling of the crystalline particles was monitored using in-situ X-ray diffraction. Cytotoxicity 
experiments showed that all iron(III) fumarate variants feature adequate bio-tolerability and no distinct interference with cellular 
metabolism at low concentrations. Magnetic resonance relaxivity studies using clinical MRI equipment, on the other hand, proved 
that the MRI contrast characteristics depend on particle size and morphology. All in all, this study demonstrates the possibility of 
tuning the morphological appearance of iron(III) fumarate particles and illustrates the importance of optimizing synthesis conditions 
for the development of new biomedical materials. 
 
Introduction 
There is a sustained demand for new colloidal nano and mi-
croparticles in biomedical applications such as drug delivery, 
imaging, cell labeling and cancer therapy.1-10 In the last two dec-
ades many new material classes have been developed that can 
be used in these applications, but these advances have also iden-
tified new problems which have to be tackled.11-13 One such 
problem is the feasibility of synthesis; biomedical applications 
desire particles that are simple to synthesize, ideally under 
aqueous conditions. Products should be of high purity, and 
monodisperse in size and shape to ensure in vitro and in vivo 
reproducibility.9 In general, particles destined for drug delivery 
should be highly porous and have functionalizable inner and 
outer surfaces to control the loading and release of drugs, to 
equip them with imaging capabilities, to improve their colloidal 
stability, and to control their interaction at the nano-biointer-
face. Of course, biomedical applications require intense study 
and control over the potential toxicity of the compounds – a 
problem that can be addressed by creating materials from bio-
compatible building blocks and ensuring biodegradability.8,9 
 Iron(III) fumarate excels in all of these categories and is 
therefore a promising candidate for biomedical use. This mate-
rial has been used to produce crystalline solids of various parti-
cle sizes for various applications (Table 1). In its crystalline 
form, iron(III) fumarate exhibits the metal-organic framework 
(MOF) structure of MIL-88A.14 The hexagonal crystal structure 
of this coordination framework consists of Fe3+ ions arranged 
into Fe3O16 iron-oxo trimers that are in turn connected by the 
bridging ligand fumaric acid (Figure S1). The resulting material 
is a microporous, flexible hybrid structure. Solvent and other 
guest molecules can penetrate into the pores and shift the lattice 
parameters such that its pore volume increases in a process 
called lattice “breathing”.15-18 Iron(III) fumarate is considered 
well tolerated since its components are ubiquitous in the human 
body; fumaric acid is a metabolite of the citric acid cycle, and 
 
iron is a trace element in our body and essential co-factor of 
many enzymes and proteins. Iron(III) fumarate particles offer 
remarkable functionality. Iron(III) fumarate nanoparticles have 
shown great compatibility with biological coatings such as ex-
osomes19, 20 and liposomes20. Coordinatively unsaturated metal-
-centers on the particles’ surface can bind Lewis bases, enabling 
post-synthetic modification.21 Therefore the synthetic material 
can be post-modified to feature hydrophilic surproperties22 or 
fluorescent centers23. Other functionalization approaches can be 
conducted during particle synthesis and introduce monovalent 
capping agents at the particle surface that carry functional 
groups.24 
In addition to this functionalizability, iron(III) fumarate of-
fers important intrinsic functionality that makes it well suited 
for clinical imaging: crystalline iron(III) fumarate hosts a sig-
nificant proportion of paramagnetic Fe3+ ions, which qualifies 
the framework as a potential contrast agent in magnetic reso-
nance imaging (MRI).25, 26 Furthermore, gold functionalized 
iron(III) fumarate particles have performed well as contrast 
agents in other clinical imaging methods such as computer to-
mography and photoacoustic imaging.26 As both a biocompati-
ble and functionalizable material, it is no surprise that there are 
numerous reports of iron(III) fumarate nano and microparticles 
being used as potential drug carriers.19-21, 23, 25, 27, 28 A summary 
of the most important biomedical and non-biomedical applica-
tions of the material are shown in Table 1. All of these applica-
tions are based on iron(III) fumarate, however their material 
properties such as particle size and shape do not appear stand-
ardized.  
Table 1. Applications of iron(III) fumarate in the literature. 




23, 25, 27, 28 
Imaging 25, 26 
Sensing 24, 29, 30 
Catalysis 31, 32 
Microparticles 
Water purification 33 
Catalysis 34-40 
Electrochemistry 38, 41, 43 
Gas storage 42 
Not specified 
Gas storage 43, 44 
Catalysis 45 
Drug Delivery 21 
 
To date, synthesis protocols of monodisperse iron(III) 
fumarate particles are not well established.46 Advances that 
were made to characterize the crystallization of this structure 
either rely on the usage of modulating additives or fail to char-
acterize the particles' functionality and biocompatibility.27, 30, 47-
49 Mastering the synthesis of iron(III) fumarate particles and un-
derstanding the relationship between their morphology, struc-
ture and their material and biological properties are imperative 
to unlock their potential for biomedical purposes. The study 
presented here therefore serves multiple purposes: (i) to system-
atically study the relationship between synthesis conditions 
(e.g. heat source, reaction parameters, solvent, reactant concen-
tration) and the morphology and crystallinity of iron(III) 
fumarate particles produced; (ii) to investigate the impact of 
morphology on the particles' intrinsic material properties (e.g. 
MRT activity and porosity); and (iii) to explore their biocom-
patibility and connect those data with the physicochemical pa-
rameters (e.g. morphology and size). 
With these goals in mind, we investigated the influence of 
different synthesis approaches (solvothermal, microwave as-
sisted, microfluidic heating, and simple room temperature pre-
cipitation) on the iron(III) fumarate system. By optimizing the 
reaction conditions such as reaction time, temperature, reactant 
concentration, and solvent, we were able to control the mor-
phology of the emerging particles, which allowed us to produce 
four isolated distinct iron(III) fumarate variants. These particles 
were then further characterized to address the three aforemen-
tioned targets: First, the iron(III) fumarate variants generated 
under different synthesis conditions were characterized by elec-
tron microscopy, electron diffraction and X-ray diffraction. 
Next, nitrogen sorption, in-situ X-ray diffraction and magnetic 
resonance data were gathered for the particles. Finally, we 
tested the particles for cytotoxicity and cell association.  
Morphological Control of Iron(III) Fumarate 
Biomedical applications require high-quality nano and mi-
croparticles generated with reproducible synthesis protocols 
that can be scaled-up and yield a product with monodisperse 
morphology and size. The growth of nanocrystalline MOFs is 
typically controlled by using modulating capping agents such 
as surfactants and short monocarboxylic acids.50 In our study 
we avoid this chemical approach as it comes with adverse side 
effects; modulating agents are often toxic, and they tend to ac-
cumulate on the outer surface of particles.51 Therefore, in this 
Figure 1. Schematic illustration of this work from left to right: The synthesis of iron(III) fumarate particles was optimized using four different 
synthesis approaches. By controlling reaction parameters four different iron(III) fumarate variants depicted here in scanning electron micro-
graphs have been isolated. These particles were then further characterized by biological and physicochemical techniques to understand the 
connection between morphology, size, porosity, functionality and biocompatibility. 
 
 
section we study the formation of iron(III) fumarate particles 
using common heating methods like conventional and micro-
wave ovens in addition to microfluidic reactors, a synthesis 
technique that has only recently captured the attention of the 
MOF community.28, 52-55 We compare particle formation in the 
most ubiquitous iron(III) fumarate synthesis solvent N,N-Dime-
thylformamide (DMF), and water which is the solvent of choice 
for any material with intended use in biomedical applications. 
Synthesis in DMF Iron(III) fumarate synthesis in DMF was 
performed by first dissolving iron(III) chloride hexahydrate in 
DMF under sonication and subsequently adding a correspond-
ing amount of fumaric acid. The resulting solution (0.2 M 
iron(III) chloride hexahydrate, 0.2 M fumaric acid) was used as 
the starting solution in all of the different synthesis approaches. 
This reaction solution was incubated for several weeks at room 
temperature (RT), but no particle formation occurred, suggest-
ing that the synthesis of iron(III) fumarate at these concentra-
tions requires heating.  
For solvothermal experiments, this stock solution was used 
in its concentrated (0.2 M) form and in a tenfold diluted con-
centration (0.02 M). The morphology and homogeneity of the 
iron(III) fumarate particles resulting from this method depend 
primarily on heating time. In order to provide the steep heating 
ramps and fast heat transfer necessary to produce well-defined 
nucleation and growth periods, solvothermal experiments with 
reaction times of less than 2 h were performed in reaction vol-
umes of 1 mL (for more reaction details see Supporting Infor-
mation). At high reactant concentrations iron(III) fumarate was 
produced after heating for 6 h at 60 °C. Increasing the temper-
ature to 120 °C shortened the reaction time to 30 min. These 
particles were micrometer-sized and exhibited homogeneous 
bipyramidal shape when first formed, however this homogene-
ity is lost upon further heating (Figure S2), which we attribute 
to the formation of new nucleation centers during the longer 
heating period. To study the influence of reactant concentration 
on iron(III) fumarate particle formation, the reactant concentra-
tion was lowered by a factor of 10. This change produced highly 
homogeneous elongated particles (Figure S3). A tenfold reduc-
tion of the reaction time improved particle homogeneity at these 
low concentration conditions even further (Figure S4). Temper-
ature decreases did not influence the resulting particle morphol-
ogy but slowed down the time for particle formation (Figure 
S4).  
Microfluidic particle growth in DMF was conducted using a 
single syringe setup that was fed with a premixed, high concen-
tration solution of all precursors into PTFE tubing. The reaction 
mixture was pumped through a heating zone of defined length, 
which allowed us to manipulate the reaction time by altering the 
rate of the reactant flow. (Figure S5). Due to the improved heat 
transfer afforded by this microfluidic setup the particles crystal-
lization time was shortened by a factor of two, to just 15 min, 
and the particle size was decreased to below 1 µm. Lower flow 
rates (and therefore longer reaction times) produced larger par-
ticles (Figure S6). Prolonged use (2 h) of this setup lead to clog-
ging in the delicate microfluidic tubing due to particle growth 
on the tubing walls.  
The challenge of creating steep heating and cooling ramps in 
DMF could be overcome by microwave heating. In these exper-
iments reaction temperatures were adjusted in less than a minute 
while providing 20 times the reaction volume of the solvother-
mal approaches and were stopped by fast quenching in cold 
DMF. Compared to microfluidic synthesis microwave heating 
at 120 °C in a 5 minute synthesis protocol has decreased particle 
size by 50% (Figure S7 and Figure S8). Further decreases in re-
action time yielded polydisperse particles at very low yields.  
Synthesis in Water Iron(III) fumarate synthesis in water was 
conducted by preparing an aqueous solution of iron(III) chlo-
ride hexahydrate and adding a stoichiometric amount of fu-
maric acid (0.2 M iron(III) chloride hexahydrate, 0.2 M fumaric 
acid). The resulting suspension was used as a stock solution for 
further experiments. Within two minutes of preparing this reac-
tion mixture, precipitation of spherical iron(III) fumarate nano-
particles can be observed (Figure S9). Over time, iron(III) 
fumarate needles embedded within a matrix of interconnected 
spherical nanoparticles emerged, and the micrometer-long nee-
dles completely exceeded the spherical particles after 4 days. 
(Figure S10). During this time, the crystallinity of the overall 
sample increased drastically (Figure S11). Elevated tempera-
tures such as in solvothermal and microwave assisted growth 
(Figure S12 and Figure S13) enhanced the speed at which this 
crystallization transformation was completed. Further reaction 
time did not change the resulting crystal product noticeably 
(Figure S13). Similar to the solvothermal growth experiments 
in DMF, these experiments were limited to reaction volumes of 
1 mL for reaction times under 1 h to ensure a sufficiently fast 
heating rate. 
For faster heat transfer and better control over reaction time 
the microfluidic setup shown schematically in Figure S5 was 
used. Syringe pumps that fed both aqueous iron(III) chloride 
and fumaric acid precursor solutions via a T-junction into 
heated PTFE tubing in a 1 : 1 ratio. These experiments require 
fully soluble precursors, and thus reactant concentrations were 
lowered twentyfold. The onset of needle formation in this mi-
crofluidic reactor corresponded to the onset observed under sol-
vothermal conditions despite the low reactant concentrations 
(Figure S14). Unfortunately, iron(III) fumarate quickly precip-
itated on the walls of the microfluidic tubing rendering the ap-
proach unfeasible for reaction times longer than 10 min. Similar 
to the other aqueous synthesis approaches, under these condi-
tions the growth of the needle morphology was preceded by the 
precipitation of spherical nanoparticles. 
Further experiments compared the efficacy of these microflu-
idic experiments to solvothermal and room temperature synthe-
sis. A tenfold diluted iron(III) fumarate solution was mixed with 
a stoichiometric amount of fumaric acid in a 1:1 ratio. These 
experiments also initially resulted in the precipitation of spher-
ical nanoparticles of iron(III) fumarate that transformed over 
time into crystalline micro-needles (Figure S15). At room tem-
perature, needle crystallization growth was considerably 
slowed while the microparticles grew in a more bulky shape 
(Figure S16).  
Material Characterization 
Through optimization of synthesis conditions as described 
above, we isolated 4 variants of iron(III) fumarate particles with 
notable homogeneity, morphology and scale-up potential. 
(Figure 2). The smallest of these particles (with diameters of 
(49 ± 12) nm) are referred to as “spherical nanoparticles”. 
These were synthesized via RT precipitation from water. The 
iron(III) fumarate “dipyramidal nanoparticles” are 
(400 ± 95) nm long and (184 ± 30) nm wide,  and were synthe-
sized in a microwave reactor in DMF. “Dipyramidal micropar-
ticles” with a diameter of (1.2 ± 0.2) µm were synthesized in 
 
DMF under solvothermal conditions. The needle-shaped micro-
particles (10 ± 2) µm long and (975 ± 420) nm wide were syn-
thesized in water using the solvothermal method (Figure S17). 
The detailed synthesis conditions of these particles are de-
scribed in the Supporting Information.  
Chemical and Colloidal stabiltiy 
In order to test the particles´ behavior in solution, dynamic 
light scattering (DLS, see Figure S23 and Table S3) and zeta 
potential measurements (see Figure S24 and Table S4) were 
performed. These experiments show that both nanoparticle var-
iants form colloidally stable suspensions in to water and etha-
nol. In HBG buffer (10 mM HEPES, 5 % glucose, pH 7.4) the 
smaller spherical nanoparticles did exhibit slight signs of ag-
glomeration while the dipyramidal nanoparticles were not af-
fected. In HEPES buffer (10 mM, pH 7.4) both nanoparticle 
types showed signs of agglomeration. This was further con-
firmed in zeta-potential measurements, where the particles gen-
erally exhibited a positive zeta potential in water (10-20 mV, 
pH 7.0) or negative zeta-potential in HBG buffer (-10 mV 
to -20 mV, pH 7.4) while being close to 0 mV in HEPES buffer 
(pH 7.4).  
Chemical stability assessments have shown that the needle 
microparticles and both nanoparticle morphologies retain their 
shape when incubated in cell medium for 24 h (Dulbecco's 
Modified Eagle's Medium, See Figure S18), while the dipyram-
idal microparticle morphology show beginning signs of degra-
dation. Overall the particles feature excellent long-term storage 
capabilities as they can be stored in ethanol at RT for many 
months (Figure S19 - Figure S22). 
X-Ray diffraction 
X-ray data was gathered for all 4 morphologies using pow-
dered samples generated via RT vacuum drying of ethanolic 
particle dispersions (Error! Reference source not found.). 
Both microparticle types and the dipyramidal nanoparticles de-
pict crystallinity with X-ray diffraction patterns corresponding 
to MIL-88A16 (Figure S1). Lattice parameter refinements of 
these 3 samples resulted in very similar values (Table 2). The 
small deviations can be attributed to the drying process of the 
flexible MIL-88A structure and distortion of the lattice. The 
spherical nanoparticles, on the other hand, appear amorphous in 
these X-ray diffraction experiments. However, we stress that 
this, as demonstrated later in this work, is only an effect of the 
small particle size. This highlights a key misconception in cur-
rent MOF literature – i.e. confusion between nanocrystalline, 
and amorphous samples. 
Table 2. Lattice parameters of the three crystalline iron(III) 
fumarate samples. 
Iron fumarate variant a (Å) c (Å) 
Needle-Shaped Microparticles 12.8678(09) 13.5139(14) 
Dipyramidal Nanoparticles 12.9307(15) 13.4325(27) 
Dipyramidal Microparticles 12.8701(12) 13.4870(17) 
Thermogravimetric analysis 
To more carefully identify the chemical relationship between 
the crystalline and the spherical iron(III) fumarate nanoparticle 
samples, we performed thermogravimetric measurements. The 
thermogravimetric data for all four samples are shown in Figure 
S25 and Table S5. The degradation behavior of the samples 
matches literature data for the MOF MIL-88A.56 All four sam-
ples undergo a two-step degradation process which indicates a 
similar chemical composition. After initial drying of the sam-
ples only a low amount (around 5-8 wt%) of residual solvent is 
physisorbed to the surface. The onset of the degradation at 
259 °C- 285 °C caused by the degradation of fumaric acid.30 Af-
ter decomposition of the organic component (52-57% of the to-
tal sample mass), XRD indicates that the residual mass of the 
samples (the remaining 37-41%) corresponds to a final compo-
sition of an iron(III) oxide than can be identified as hematite 
(Figure S25).  
Electron diffraction 
For further structural and morphological characterization of 
the less crystalline spherical nanoparticles, transmission elec-
tron microscopy (TEM) was performed. TEM images showed 
particles of uniform size between 20-30 nm (Figure 4). Several 
particles exhibited lattice fringes that quickly vanish during il-
lumination. More gentle electron diffraction (ED) of larger ar-
eas resulted in broadened Bragg-rings confirming that a sub-
stantial percentage of the particles exhibit crystalline domains 
(Figure 4). ED patterns match the lattice distances as well as the 
expected intensity distribution for MIL-88A.16 Figure 4 shows 
a comparison of an experimental ED pattern after azimuthal in-
tegration and background subtraction and an ED simulation of 
Figure 2. SEM micrographs depicting the morphology of the four 
variants of iron(III) fumarate that are used for further characteriza-
tion. Top left: spherical nanoparticles, top right: needle-shaped mi-
croparticles, bottom left dipyramidal microparticles, bottom right: 
dipyramidal nanoparticles. 
Figure 3. X-ray diffraction patterns of the morphologically distinct 
iron(III) fumarate samples 
 
iron(III) fumarate with MIL-88A structure. The best fit with re-
spect to reflection broadening was obtained by the Scherrer 
equation: 3.5 nm along the a- and b-axes and approximately 1 
nm along the c-axis of the hexagonal unit cell. 
 Pair distribution function analysis 
To complement the data acquired from electron diffraction, 
X-ray total scattering experiments were performed at the I15-1 
beamline at the Diamond Light Source, UK (λ = 0.161669 Å-1), 
on all four samples. The total scattering structure factors S(Q)s 
(Fig. S27) were extracted after appropriate data corrections.57 
The sharp Bragg features visible in the S(Q) for the spherical 
nanoparticles clearly identify the sample as crystalline, and 
therefore distinct from amorphous solid or metal-organic 
framework glasses, where only smooth features in the structure 
factors are observed.58, 59 The pair distribution functions, D(r) 
for all four samples were obtained upon Fourier Transform (Fig. 
5). Identical atom-atom correlations are evident up to ca. 12 Å. 
PDFgui software60 was used to identify the atom-atom correla-
tions responsible for peaks in the 0 – 12 Å region (Fig. S28). 
These assignments are labelled in the PDFs (Fig. 5), and show 
that the correlations appear due to near identical links between 
Fe3O clusters. Above 12 Å, i.e. the medium range order, corre-
lations within the spherical nanoparticles reduce drastically, 
which is broadly consistent with the electron microscopy data 
and the nanoparticulate nature of the sample. It is also interest-
ing to note that the sample of dipyramidal microparticles is dis-
similar at this scale to both ther the needle or dipyramidal na-
noparticle sample, though continues to display crystallinity to 
ca. 40 Å (Fig. S29).  
Nitrogen sorption 
Porous materials are excellent candidates for drug delivery 
systems because their vast internal surface area is readily acces-
sible via pores. To determine the surface area of the iron(III) 
fumarate samples nitrogen sorption experiments were per-
formed and analyzed with the BET method. All samples show 
surface areas of 120 to 450 m²/g (Table S7) in agreement with 
literature values, which range from 15 to 580 m²/g depending 
on reaction conditions and sample preparation methods.23, 37, 42 
As particle size decreases the experimentally determined BET 
surface areas of the particles increase. This effect can partially 
(30 %) be explained by the increased surface to volume ratio 
due to the nano dimensions of the particles (see supporting In-
formation “Calculation of the theoretical surface depending on 
particle size”). Additionally we attribute the increased surface 
area to texturing during the drying of the particles that results in 
an increasing slope in the sorption isotherms for the smaller par-
ticle types after their micropores are filled (Figure S30). All 
iron(III) fumarate variants (Figure S31) show a similar pore size 
distribution (11-13 Å). The aforementioned texturing effect can 
also be monitored in the pore size distributions as decreasing 
particle size leads to mesopores in the smaller spherical nano-
particles and dipyramidal nanoparticles. 
Breathing behavior 
While nitrogen sorption experiments can predict the surface 
area of a material, the actual loading and release of potential 
drugs is conducted in solvent systems. The MIL-88A structure 
of crystalline iron(III) fumarate is known for its flexible pores 
that expand upon solvent incorporation.16 The data shown in 
Figure S32-S34 is generated from in-situ X-ray diffraction on 
each of the higher crystallinity iron(III) fumarate variants using 
Figure 5. a) Electron diffraction pattern and b) TEM micrograph 
of spherical iron(III) fumarate nanoparticles. c) Azimuthally inte-
grated electron diffraction pattern after subtraction of the mean 
scattering intensity (black) compared to the theoretical diffraction 
pattern of MIL-88A nanoparticles (red). 
 
Figure 4. Pair distribution functions D(r) (upper) and correspond-
ing labelled partial structure of MIL-88A showing two iron oxide 
metal clusters linked by a fumarate ligand (lower) (red – oxygen, 
orange – iron, dark grey – carbon, white – hydrogen).  
 
various solvents that would typically be encountered in biolog-
ical applications. During these experiments the particles re-
tained their crystallinity for several hours. Powder XRD pat-
terns were used to refine the lattice parameters of the different 
iron(III) fumarate variants in their respective solvent combina-
tions. As shown in Table 3, the lattice dimensions of these 
iron(III) fumarate variations in each of the different solvent sys-
tems was controlled with a volume change of up to 12% as sol-
vent conditions changed, regardless of morphology. 
Table 3. Lattice parameter evolution upon exposure of the 
higher crystalline iron(III) fumarate variants to various sol-
vents. 
Solvent a (Å) c (Å) Volume 
Needle-shaped Microparticles 
DMSO 14.506(21) 11.828(15) 2155.4(38) 
H2O 13.830(8) 12.702(6) 2103.9(14) 
EtOH 13.636(5) 12.812(4) 2063.2(9) 
MeOH 12.863(6) 13.584(6) 1946.4(11) 
DMF 12.92(3) 13.385(19) 1933.7(37) 
Dipyramidal Nanoparticles 
DMSO 14.620(4) 11.722(4) 2169.9(8) 
H2O 13.880(21) 12.711(4) 2120.7(39) 
EtOH 13.616(8) 12.844(7) 2062.1(15) 
MeOH 12.90(6) 13.60(3) 1961.3(113) 
DMF 12.820(7) 13.638(12) 1941.0(19) 
Dipyramidal Microparticles 
DMSO 14.647(13) 11.728(9) 2178.9(27) 
H2O 13.873(14) 12.659(10) 2109.9(25) 
EtOH 13.629(10) 12.835(8) 2064.8(17) 
MeOH 12.86(10) 13.585(11) 1945.8(20) 
DMF 12.829(9) 13.625(8) 1942.1(16) 
MRI measurements 
MIL-88A nanoparticles proved to be excellent MRI contrast 
agents during in vivo experiments.61 Contrast between different 
tissues occurs because the protons of water molecules in differ-
ent tissues exhibit different longitudinal and transverse relaxa-
tion times in a magnetic field. MRI contrast agents enhance 
these differences further by decreasing the longitudinal (T1) or 
transverse (T2) relaxation times of the tissues that house them. 
The MOF MIL-88A is believed to influence this behavior be-
cause its paramagnetic iron(III) centers are imbedded in a po-
rous framework and are therefore easily accessed by water.61, 62 
The inverse of these relaxation times, i.e. Ri = 1/Ti (i = 1,2), are 
determined to measure the strength of a potential contrast agent 
at particular concentrations. Typically, the Ri values display a 
linear dependency on the concentration of the contrast agent; in 
such cases, the slope is called the relaxivity and indicates the 
effectiveness of the contrast agent in shortening the relaxation 
times of water protons. In the experiments presented here, we 
determined the relaxivity of the four iron(III) fumarate variants 
in a clinical MRI setting at 1.5 T. These measurements were 
performed either in Xanthan gel (in case of the microparticle 
variants) or in water (in case of the spherical nanoparticles).  
The mass-based relaxivities of the dipyramidal and nee-
dle-shaped iron(III) fumarate particles are inversely related to 
the particle size (Table 4). Surprisingly, the spherical nanopar-
ticle sample do not follow this trend and have low r2 values. In 
literature, other factors such as agglomeration, crystallinity and 
particle shape have been shown to influence the relaxivities of 
nanoparticles63-66. Experimentally determined mass-based re-
laxivities are additionally depicted as particle-based relaxivities 
(Supporting Information, Figure S37). Here, both the r1 and r2 
relaxivities of a single particle tend to increase with its size. 
This may be explained by the increasing number of paramag-
netic iron centers in larger particles. To compare our results 
with commercially used contrast agents, the experimentally de-
termined mass-based relaxivities were converted to molar re-
laxivities (Supporting Information, Figure S37). In this depic-
tion the amount of iron(III) ions in the sample is considered. 
The iron(III) fumarate particles in this study achieve 3-8% of 
the molar relaxivities of iron-based R2 contrast agents such as 
Feridex (41 L mmol-1 s-1)67. However, the dipyramidal nanopar-
ticles have R1 relaxivities of the same magnitude as commer-
cially available R1 contrast agents, with approximately ~40% of 
the strength of gadoteric acid (2.9 L mmol-1 s-1).67 These results 
confirm the overall potential of iron(III) fumarate as MRI con-
trast agent, especially since the particles can simultaneously be 
used in drug delivery. 
Table 4. Mass-based relaxivities of iron(III) fumarate particles 









1.46 ± 0.03 8.6 ± 0.5 
Dipyramidal 
Microparticles 
2.16 ± 0.02 15.7 ± 0.2 
Dipyramidal 
Nanoparticles 
6.094 ± 0.004 18.8 ± 0.4 
Spherical Nano-
particles 
4.23 ± 0.02 5.93 ± 0.03 
Biological characterization 
After establishing the synthesis of monodisperse iron(III) 
fumarate nano and microparticles and their physicial and func-
tional characterization, we wanted to understand the impact of 
different morphologies on cellular interactions and biological 
criteria that are important for biomedical applications. To do 
this, we conducted toxicity and cell association experiments. 
Cellular interaction 
Fluorescence quenching effects make iron(III) fumarate par-
ticles hard to label and detect by fluorescence techniques,68 so 
instead cellular interaction and association were investigated by 
inductively coupled plasma optical emission spectroscopy 
(ICP-OES). In these experiments, the iron content in HeLa cells 
before and after incubation with the particles was compared. To 
do this, aqueous dispersions of the iron(III) fumarate variants 
were incubated with HeLa cells for 24 h at a concentration of 
100 µg/mL. Then the medium was separated from the cells, 
both fractions were dried and the iron-content of each fraction 
was determined via ICP-OES. This method allows us to com-
pare the amount of iron associated with HeLa cells (membrane 
bound and internalized) and amount left in the supernatant. The 
relative amount of nanoparticles associated with the cells was 
then determined by relating the mass of iron(III) ions detected 
in the cell to the overall mass of iron(III) ions in the experiment 
(cells and supernatant). As a reference, nanoparticle-independ-
ent iron(III) uptake was tested using an iron(III) chloride-solu-
tion containing the same iron(III) amount as used in the particle 
uptake experiments. Additionally, the iron(III) content of the 
untreated cells was examined by the same method. The raw data 
from these experiments (see Table S8) suggests association of 
all four iron(III) fumarate variants with HeLa cells (15 to 66%, 
 
Table 5). The untreated cells did not have any detectable levels 
of iron(III). Unspecific uptake of free Fe3+ caused by particle 
degradation is considered negligible because Fe3+ ion uptake in 
the control experiment was very low (3 %). In addition, stability 
measurements of the particles in cell culture medium showed 
that all particle types retained their morphology (so there was 
no reason to suspect any significant degradation). The micro-
meter sized particles produced the highest cellular iron increase; 
in general particle size could be correlated with cellular associ-
ation. This observation may be explained by higher sedimenta-
tion and greater cellular uptake or external binding of larger par-
ticles in static cell culture conditions. Similar phenomena have 
also previously been described in context of other nanomateri-
als.69  
Table 5. Fraction of iron(III) fumarate associated to HeLa cells 
after 24 h incubation as determined by ICP. 
Sample Uptake 
Spherical Nanoparticles (15.0 ± 0.3)% 
Dipyramidal Nanoparticles (29 ± 1)% 
Dipyramidal Microparticles (59 ± 2)% 
Needle-shaped Microparticles (66 ± 3)% 
Free Fe3+ (3 ± 0.5)% 
Cytotoxicity 
Despite the identical chemical composition of all 4 iron(III) 
fumarate variants, their individual synthetic routes and unique 
morphologies could cause different effects on cellular metabo-
lism and viability. To sasses the biological effects of each 
iron(III) fumarate type, human cervix carcinoma HeLa cells 
were incubated with aqueous dispersions of the individual par-
ticles at different concentrations. After 24 h, 48 h and 72 h the 
metabolic activity was determined in comparison to control 
cells without particle exposure by MTT (measuring cellular re-
duction potential) and CellTiter-Glo (measuring cellular ATP 
levels) assays. As shown in Figure 6 (MTT and CellTiterGlo), 
all iron(III) fumarate variants did not mediate distinct effects on 
cell viability within 24 h exposure at concentrations up to 200 
µg/mL  (metabolic activity >80%). At high concentrations 
(200 µg/mL) and longer incubation times (48 h and 72 h) the 
cells showed reduced viability indicating beginning toxicity. 
This is especially prevalent for incubation with the spherical na-
noparticles. A hypothetical explanation could be the induction 
of reactive oxygen species (ROS) generation by internalized 
iron(III). ROS generation was investigated with a ROS-
sensitive cell staining (2’,7’-dichlorofluorescein diacetate, 
DCFDA) and flow cytometry (Figure S39). Here, slightly 
higher cellular fluorescence was detected after treatment with 
iron(III) fumarate particles, in particular with spherical mor-
phology. Nevertheless, considering the high doses required for 
induction of effects on cell viability, all types of analyzed 
iron(III) fumarate particles are suggested to exhibit rather low 
cytotoxicity and adequate cellular tolerability. Notably, also the 
iron(III) fumarate variants synthesized in DMF did not exhibit 
an increased cytotoxicity compared to the variants synthesized 
in water.  
Conclusion 
At first glance, iron(III) fumarate seems to fulfill the strict 
requirements of nano- and microparticles to be used in biomed-
icine. However, the material possesses great morphological and 
structural variety (Table 1) and the impact on biomedical func-
tionality and biocompatibility is insufficiently explored. In this 
work, the influence of different surfactant-free iron(III) 
fumarate synthesis methods have been explored and the result-
Figure 6. Cytotoxicity of iron(III) fumarate particles. Viability of HeLa cells after 24 h, 48 h and 72 h incubation with iron(III) 
fumarate particles as determined by MTT assay (top) and CellTiterGlo assay (bottom). 
 
ing particles characterized by X-ray diffraction, nitrogen sorp-
tion, thermogravimetry, spectroscopy, electron microscopy, 
MRI and biological assays.  
Four different synthesis routes (RT precipitation, and sol-
vothermal, microwave and microfluidic heating methods) were 
optimized in water and DMF. While the microfluidic approach 
addressed the fundamental challenges of controlled heat distri-
bution and precise reaction time, solvothermal and micro-
wave-based techniques were found to be better suited for scal-
ing up production. In the water-based synthesis methods, 
iron(III) fumarate generation occurred in two-steps: first the 
formation of spherical iron(III) fumarate nanoparticles, then 
subsequent crystallization of needles. For iron(III) fumarate 
growth in DMF conventional heating in an oven and microflu-
idic reactor methods yielded micrometer sized particles. Micro-
wave synthesis turned out to be the most efficient technique to 
generate dipyramidal nanoparticles. This technique enabled 
quick and facile production of homogeneous particles in large 
quantities. Overall this optimization resulted in 4 different ho-
mogenous varieties of iron(III) fumarate that spanned the nano- 
to microparticle scale and the individual synthesis procedures 
have potential for large scale production  
Although all four materials are iron(III) fumarate by chemical 
composition, they differ in their porosity and functionality. All 
particle types crystallize in the MOF structure MIL-88, but the 
extent of crystallinity in the smallest nanoparticles is limited to 
a few nanometers. In-situ X-ray diffraction confirmed the typi-
cal breathing behavior of MIL-88A for all higher crystalline 
iron(III) fumarate variants. Lattice parameters and cell ex-
panded up to 12% through solvent exchange, a desirable feature 
when designing materials for drug delivery since this expansion 
allows drug cargo to easily load. Regardless of the synthesis 
method, all iron(III) fumarate variants were shown to exhibit 
adequate cellular tolerability. Only at high concentrations 
(200 µg/mL) and long incubation times (48 h and 72 h) distinct 
effects on cell viability could be detected, especially in case of 
the spherical nanoparticles. Iron(III) fumarate also possesses in-
teresting intrinsic functionality; its paramagnetic iron(III) cen-
ters render them suitable for MRI contrast agents. In MRI ex-
periments the importance particle size optimization becomes 
apparent: by reducing the particle size of the higher crystalline 
iron(III) fumarate variants r2 relaxivities can be doubled and r1 
relaxivities can be quadrupled.  
We have studied the influence of morphological and struc-
tural optimization on nano and microparticles of iron(III) 
fumarate. Characterization of the resulting four particle variants 
was conducted to assess their applicability in biomedicine. Our 
study demonstrates the importance of precise synthesis control 
in improving the performance of such materials. 
Experimental Section 
Chemicals: Ethanol (VWR, 99.9%), Iron(III) chloride hexahy-
drate (Grüssing, 99%), Fumaric acid (Sigma, ≥99.0%), N,N Di-
methylformamide (DMF, VWR, 99.9%), Xanthan gum from 
Xanthoma campestris (Sigma). 
Synthesis of the 4 different Iron(III) fumarate Variants: In 
this short section, the synthesis protocols used to generate each 
of the four iron(III) fumarate variants that were later character-
ized for functionality and biocompatibility are shown. 
Spherical Nanoparticles: A solution of 
FeCl3 · 6 H2O (2168 mg, 8.02 mmol) in water (40 mL, Merck, 
Milli-Q) was prepared. Fumaric acid (970 mg, 8.36 mmol) was 
added under stirring. After incubation at room temperature 
(2 min) the reaction was stopped and washed three times by 
centrifuging (7197 rcf, 20 min) and redispersing in ethanol. 
Needle-shaped Microparticles: A reaction mixture of fumaric 
acid (485 mg, 4.18 mmol) and FeCl3 · 6 H2O (1084 mg, 
4.01 mmol) in water (20 mL, Merck, Milli-Q) was prepared. 
The reaction mixture was placed in a 50 mL Schott glass vial 
and put into an oven for 24 h at 80 °C. The resulting particles 
were washed three times by centrifuging (7197 rcf, 20 min) and 
redispersing in ethanol. 
Dipyramidal Nanoparticles: Fumaric acid (485 mg, 
4.18 mmol) and FeCl3 · 6 H2O (1084 mg, 4.01 mmol) were dis-
solved in DMF (20 mL). This reaction mixture was placed in a 
80 mL Teflon tubes and put in a microwave reactor (Synthos 
3000, Anton Paar) along with a reference solution containing 
FeCl3 · 6 H2O (1084 mg, 4.01 mmol) in DMF (20 mL) and two 
additional vessels containing tap water (20 mL). A reaction pro-
gram consisting of first heating the sample for 30 s up to 120 °C 
and subsequent holding of this temperature for 5 min was used. 
At the end of this program the reaction was quenched by pour-
ing the hot reaction mixture in DMF (room temperature, 
50 mL). The resulting product was washed with DMF (40 mL) 
washed three times by centrifuging (7197 rcf, 20 min) and re-
dispersing in DMF. 
Dipyramidal Microparticles: A stock solution of fumaric acid 
(194 mg, 1.67 mmol) and FeCl3 · 6 H2O (433 mg, 1.604 mmol) 
in DMF (8 mL) was prepared and divided equally into eight 
1.5 mL Eppendorf tubes. The reaction mixtures were placed in 
an oven for 30 min at 120 °C. The resulting particles were 
washed washed three times by centrifuging (16873 rcf, 10 min) 
and redispersing in DMF. 
Additional Information 
Additional content for this publication is provided in the Sup-
porting Information that can be accessed free of charge at 
http://pubs.acs.org.The following additional data is provided in 
the Supporting Information: 
 Instrumental parameters and description of the setups 
 Details on the screening of iron(III) fumarate particle 
growth (SEM micrographs, X-ray diffraction data) 
 More detailed data and discussion for comparing the 
four iron(III) fumarate types: dynamic light scattering, 
Zeta-potential data, X-ray diffraction, in-situ X-ray 
diffraction, pair distribution function analysis, elec-
tron diffraction, nitrogen sorption,. thermogravimetry, 
particle size evaluation, MRI measurements 
 Information on the biological assays: MTT, CellTiter-
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